BioNTech SE (BNTX)

196.00
-6.99(-3.44%)
After Hours
196.50
+0.50(+0.26%)
- Real-time Data
  • Volume:
    2,863,828
  • Bid/Ask:
    196.16/196.50
  • Day's Range:
    194.61 - 206.24

BNTX Overview

Prev. Close
202.99
Day's Range
194.61-206.24
Revenue
15.74B
Open
195.56
52 wk Range
90.29-462.56
EPS
33.76
Volume
2,863,828
Market Cap
47.34B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
3,300,813
P/E Ratio
5.93
Beta
-
1-Year Change
92.93%
Shares Outstanding
241,521,065
Next Earnings Date
Apr. 05, 2022
What is your sentiment on BioNTech SE?
or
Market is currently closed. Voting is open during market hours.

BioNTech SE Company Profile

Employees
2800

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellBuy
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellNeutral
SummaryStrong SellStrong SellStrong SellStrong SellNeutral
  • Will continue to rise! Not just pandemic time! No doubt:)
    0
    • End of Pandemic, BNTX stock will be still very promising. Not just for today!
      0
      • Time to buy more. Best choice, approval one!
        0
        • BioNTech&Pfizer: The Best stock to buy right now. Will go up no doubth.
          0
      • Should be strong buy!
        0
        • Pfizer & BioNTech Got 'Full FDA Approval' For Its COVID Vaccine
          0
          • This is criminal!
            0
            • Wtf
              0
              • Analyst target $115
                0
                • Time to get back to 31 i guess
                  3
                  • whats better this one or pifzer
                    0
                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.